Geron Cellvain and PIRDMA Successfully Conclude the "2026 PDRN Symposium"

On the 23rd, Geron Cellvain, a company that manufactures prescription drugs, announced that the "2026 2nd PDRN Symposium," sponsored by the company and hosted by the PDRN Immune Regenerative Dental Medicine Association (PIRDMA), had successfully concluded.

The symposium brought together more than 300 medical specialists and featured extensive discussions ranging from the scientific mechanisms of polydeoxyribonucleotide (PDRN) and clinical application cases to future strategies for industrial expansion.

Speakers included Geron Cellvain CEO Kim Deokkyu; PIRDMA Vice President and Director of Yeon Dental Clinic Yoon Jongil; Professor Park Wonseo of Yonsei University Dental Hospital; Professor Koo Kitae of Seoul National University Dental Hospital; Professor Kwon Yongdae of Kyung Hee University Dental Hospital; Professor Koo Jeongkwi of Seoul National University Bundang Hospital; Professor Kim Youngjun of Youngsan University; Director Kim Yongjin of Yesmir Dental Clinic; Director Kim Hyungjun of OFP Oral Medicine Dental Clinic; and Director Jang Hyeondong of Hyun Hospital, who also serves as President of the Korean Academy of Manual Medicine.

PIRDMA President Kim Jaehong expressed his gratitude to the leading domestic speakers in the PDRN field and highlighted the potential of Geron Cellvain's prescription drug "Selvain Injection," which is widely known in dental clinical practice, based on various basic studies and clinical outcomes.

In particular, the symposium focused on the potential applications of Geron Cellvain's prescription drug "Selvain Injection" not only in dental and bone immunology, but also across a wide range of wellness and medical fields, including skin regeneration and aesthetics, in connection with its physiological properties such as promoting tissue regeneration and exerting anti-inflammatory effects.

According to the company, participants shared the latest research trends and real-world application cases, showing strong interest in the role that PDRN-based solutions could play in the next-generation bio market.

PIRDMA Vice President and Yeon Dental Clinic Director Yoon Jongil said, "Fundamental treatment of our body begins with immunity," adding, "Focusing on activating the 'Natural Healing Process' that restores damaged tissue, PDRN consists of DNA fragments extracted from salmon testes and helps both regulate inflammation and regenerate tissue."

Director Yoon explained the relationship between PDRN's mechanism of action, which centers on alleviating excessive inflammatory responses and creating an environment conducive to tissue regeneration, and the clinical recovery process, and suggested that its relatively low burden of drug-drug interactions offers significant potential for expanding combination therapy strategies.

Geron Cellvain CEO Kim Deokkyu stated, "This second symposium further concretized the scientific evidence and clinical value of PDRN," and added, "Through the experiences and research findings of medical professionals from various specialties, we confirmed that the scope of application for Geron Cellvain's 'Selvain Injection' is continuously expanding."

He went on to emphasize, "We will continue to pursue the standardization and advancement of PDRN-based therapies through ongoing research and development and academic exchanges, and provide solutions that offer tangible benefits in clinical settings."